Nova Eye Medical (ASX:EYE) has reported a record sales performance for the December 2025 quarter, with global revenue reaching US$6.1 million, up 38% on the prior corresponding period and 25% on the September 2025 quarter.
The company also recorded six-month sales of US$10.9 million, a 29% increase on the the year-ago period and last twelve months revenue of approximately US$21 million, representing 24% growth on the prior year—three times the estimated ~8% industry growth rate.
Growth was led by the United States, which achieved six consecutive halves of sales growth at a compounded annual growth rate of ~40%, and continued expansion in Rest of World markets.
The company's iTrack technology has now been used in around 180,000 surgical cases worldwide, reflecting rising recognition of its minimally invasive, rejuvenative approach.
Sales in China are expected to commence in 2026 following regulatory approval of iTrack Advance in September 2025.